Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse.
about
Persistent RNA virus infections: do PAMPS drive chronic disease?Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A.Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid.Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia.Prevalence and Distribution of Leishmania RNA Virus 1 in Leishmania Parasites from French GuianaSevere Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus.Tilting the balance between RNA interference and replication eradicates Leishmania RNA virus 1 and mitigates the inflammatory response.Unraveling the genetic diversity and phylogeny of Leishmania RNA virus 1 strains of infected Leishmania isolates circulating in French GuianaAlice in microbes' land: adaptations and counter-adaptations of vector-borne parasitic protozoa and their hosts.Chemotherapy of leishmaniasis: present challenges.Detection and molecular identification of leishmania RNA virus (LRV) in Iranian Leishmania species.Low frequency of LRV1 in Leishmania braziliensis strains isolated from typical and atypical lesions in the State of Minas Gerais, Brazil.Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor.Influence of Leishmania RNA Virus-1 on Pro-Inflammatory Biomarker Expression in a Human Macrophage Model of American Tegumentary Leishmaniasis.Development of a semi-automated image-based high-throughput drug screening system.Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.Viral discovery and diversity in trypanosomatid protozoa with a focus on relatives of the human parasite Leishmania.How to master the host immune system? Leishmania parasites have the solutions!When do coinfections matter?Leishmania guyanensis parasites block the activation of the inflammasome by inhibiting maturation of IL-1β.PD-L1 May Mediate T-Cell Exhaustion in a Case of Early Diffuse Leishmaniasis Caused by Leishmania (L.) amazonensis.New insights into the genetic diversity of Leishmania RNA Virus 1 and its species-specific relationship with Leishmania parasites.The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.
P2860
Q28804036-83CFBDFB-D2FB-484F-9EA8-029FD7CAF01CQ30275257-B7796D5C-2750-4C43-B2F3-511D2AB51908Q36141241-CC12049E-48F6-4945-B800-B7BEFD4A095EQ36252516-7C856A88-91BB-4855-88F3-2128E3ABF82EQ36365284-40A5B503-3176-450E-8702-610669F06C4AQ36455733-98352A6F-0E17-4634-AE8F-DA102AAF9072Q36776096-4AB3B3BF-9B4B-44F9-B1E4-A4A41C420133Q37379910-1D624BFF-D33A-4502-A218-752265D1A3D3Q38675651-121DA3CC-9A1F-48A4-94F0-C51840608419Q38892717-EB6B0EC2-809B-4649-AA30-A12A246765F6Q39011875-55125D08-F5DC-4DF4-9DED-E0C98AF78281Q39413677-58287217-EF02-4D3E-8E8C-CCA5BC36825CQ39468802-13380FFF-E5DD-48D2-883A-9AC33FFA0B57Q40229581-B680B1E5-CD10-4EA6-A70C-C1779EF84D12Q40368500-C8CA3346-5A3E-45E2-B62A-6E7C8C054BB6Q41926518-D04D665D-967E-461C-8205-467163F2E899Q41933768-3C0FCF62-4159-4134-90B7-924EEF775E2EQ46380663-C53BC44B-A76B-46D3-A9E5-4DAF45E0FF3BQ47237372-B73C3CA9-97FA-4573-974E-EFA4821B4F92Q52401290-89A80891-5021-4FEE-A13C-182A7F9F8C24Q53835536-ADDF32AD-3394-4B1A-8F39-69FD30C12B61Q54265327-739BC857-F257-40B3-99D1-1C7F124E3D34Q54943471-042B7452-1E64-46DF-9EBA-F60395D6EFDEQ55313067-3BAF93E5-FC6C-447A-976B-13E616A2EFEEQ55408705-19289D84-F5B5-4463-BE55-2992D3F55206
P2860
Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Presence of Leishmania RNA Vir ...... ilure and Symptomatic Relapse.
@en
type
label
Presence of Leishmania RNA Vir ...... ilure and Symptomatic Relapse.
@en
prefLabel
Presence of Leishmania RNA Vir ...... ilure and Symptomatic Relapse.
@en
P2093
P50
P356
P1476
Presence of Leishmania RNA Vir ...... ilure and Symptomatic Relapse.
@en
P2093
Antoine Bertolotti
Dominique Sainte-Marie
Eliane Bourreau
Florence Robert-Gangneux
Francine Pratlong
Frédéric Schütz
Jean-Pierre Gangneux
Julie Dufour
Marine Ginouves
Mary-Anne Hartley
P304
P356
10.1093/INFDIS/JIV355
P407
P577
2015-06-29T00:00:00Z